朊蛋白在乳腺癌MDA-MB-435细胞凋亡过程中的功能研究
|
摘要
目的：探讨细胞朊蛋白(PrPc)在不同因素导致的乳腺癌细胞凋亡中的功能。
方法：RNAi逆转录病毒载体进行PrPc表达下调稳定细胞系的构建；免疫荧光的方法对目的蛋白进行定位和半定量；MTT法测定细胞的活性；台盼蓝染色法测定死活细胞的比率；利用Western-bloting方法进行蛋白表达的检测。
结果：MDA-MB-435细胞系是雌激素受体阴性且PrPc表达量较高的细胞系,利用RNAi逆转录病毒载体构建了PrPc表达下调的稳定细胞系MDA-MB-435-siPrP(简写成：siPrP)及其对照细胞系MDA-MB-435-siLuc(简写成：siLuc)。 Western-bloting及免疫英光的结果显示经RNA干扰后MDA-MB-435-siPrP细胞系的PrPc的表达被显著的抑制。
给予不同的条件处理稳定细胞系,我们发现：各种不同因素导致的细胞凋亡中,PrPc所起的作用不同。(1)在阿霉素处理和葡萄糖剥夺情况下,siPrP细胞系比si Luc细胞系更具有耐受性,说明此种情况下PrPc具有促凋亡功能；(2)在鱼藤酮处理情况下,siPrP细胞系比siLuc细胞系更易于死亡,说明此种情况下PrPc具有抗死亡功能；(3)然而在过氧化氢(H2O2)、紫杉醇及星形孢菌素处理的情况下,siPrP细胞系与siLuc细胞系没有出现明显的差异。为了去除稳定细胞系建系过程中由于抗生素筛选而对细胞系引起的附加效应,我们在瞬时转染siPrP及其对照siLuc的质粒于MDA-MB-435细胞系；转染48小时后,检测转染效率,并重复阿霉素实验,结果发现PrPc下调的细胞系仍有对阿霉素耐受性的现象；表明阿霉素对siLuc和siPrP两种细胞系的不同影响并不是由于稳定细胞系构建过程本身引起的,而是由于PrPc表达下调引起的。
随后我们对siPrP细胞系耐受阿霉素处理的机制进行研究,发现阿霉素处理后siPrP细胞系p-p53的表达高于siLuc细胞系；由于MDA-MB-435细胞系的p53是突变体,因此我们在稳定细胞系的基础上转入有转录功能的p53,实验结果显示上调p53后siPrP-p53仍表现对阿霉素的更加耐受性,所以证明了：PrPc在阿霉素处理情况下的抗凋亡功能与p53通路无关。
Objective:To investigate the role of cellular prion protein (PrPc) in breast cancer cells apoptosis.
Methods:Using Western-bloting method for protein detection; immune fluorescence method for target protein localization and semi quantitative analysis; retroviral vector RNAi for establishing PrPc knockdown stable cell lines; MTT method for the determination of cell viability and normal cell growth curve; trypan blue staining method for determining live/dead cell ratio.
Results:The MDA-MB-435cell line is a estrogen receptor negative and PrPc high expression human breast cancer cell line. PrPc knockdown stable cell lines (abbreviated as MDA-MB-435-siPrP:siPrP) and control cell lines (abbreviated as MDA-MB-435-siLuc:siLuc) were successfully constructed using retroviral vectors expressing RNAi targeting PrP or luciferase.
Our results revealed that PrPc plays dramatically different roles in cell death caused by various factors.(1) In Doxorubicin treatment or glucose deprivation, siPrP cell line exhibited significantly more tolerance than siLuc cell lines, indicating a pro-apoptotic function of PrPc;(2) however, in rotenone-induced cell death, a higher cell death was observed in siPrP cell line compared to the control siLuc cells, suggesting an anti-apoptotic function of PrPc;(3) in hydrogen peroxide (H2O2), paclitaxel and staurosporine treatments, siPrP cells and siLuc cell lines did not show clear differences, suggesting that PrPc does not play a significant role in these cell death processes. Our results showed that, in the same cell line, PrPc may play different roles in cell deaths induced by various factors. In order to remove the additional effect caused by the stable cell line establishment process due to antibiotic screening of cell lines, we in transiently transfected siPrP and controlled siLuc plasmid to MDA-MB-435cell lines;48hours after transfection, repeat the doxorubicin experiment,results showed that PrPc downregulation of cell lines are still on adriamycin tolerance phenomenon; that of doxorubicin on siLuc and siPrP two cell lines of different effect was not due to stable cell lines construction process, but because of PrPc expression downregulated.
Moreover,research on the mechanism of siPrP cell tolerance by doxorubicin treatment, we found that siPrP cell line p-p53expression was higher in siLuc cell line after doxorubicin treatment,; due to MDA-MB-435cell line p53mutants, we transfect widetype p53in stable cell lines, the experimental results show that after up-regulation of p53,siPrP-p53were still more tolerance on doxorubicin treatment,we also showed that the pro-apoptotic function of PrPc in Doxorubicin-treated siPrP cells is p53pathway independent.
方法：RNAi逆转录病毒载体进行PrPc表达下调稳定细胞系的构建；免疫荧光的方法对目的蛋白进行定位和半定量；MTT法测定细胞的活性；台盼蓝染色法测定死活细胞的比率；利用Western-bloting方法进行蛋白表达的检测。
结果：MDA-MB-435细胞系是雌激素受体阴性且PrPc表达量较高的细胞系,利用RNAi逆转录病毒载体构建了PrPc表达下调的稳定细胞系MDA-MB-435-siPrP(简写成：siPrP)及其对照细胞系MDA-MB-435-siLuc(简写成：siLuc)。 Western-bloting及免疫英光的结果显示经RNA干扰后MDA-MB-435-siPrP细胞系的PrPc的表达被显著的抑制。
给予不同的条件处理稳定细胞系,我们发现：各种不同因素导致的细胞凋亡中,PrPc所起的作用不同。(1)在阿霉素处理和葡萄糖剥夺情况下,siPrP细胞系比si Luc细胞系更具有耐受性,说明此种情况下PrPc具有促凋亡功能；(2)在鱼藤酮处理情况下,siPrP细胞系比siLuc细胞系更易于死亡,说明此种情况下PrPc具有抗死亡功能；(3)然而在过氧化氢(H2O2)、紫杉醇及星形孢菌素处理的情况下,siPrP细胞系与siLuc细胞系没有出现明显的差异。为了去除稳定细胞系建系过程中由于抗生素筛选而对细胞系引起的附加效应,我们在瞬时转染siPrP及其对照siLuc的质粒于MDA-MB-435细胞系；转染48小时后,检测转染效率,并重复阿霉素实验,结果发现PrPc下调的细胞系仍有对阿霉素耐受性的现象；表明阿霉素对siLuc和siPrP两种细胞系的不同影响并不是由于稳定细胞系构建过程本身引起的,而是由于PrPc表达下调引起的。
随后我们对siPrP细胞系耐受阿霉素处理的机制进行研究,发现阿霉素处理后siPrP细胞系p-p53的表达高于siLuc细胞系；由于MDA-MB-435细胞系的p53是突变体,因此我们在稳定细胞系的基础上转入有转录功能的p53,实验结果显示上调p53后siPrP-p53仍表现对阿霉素的更加耐受性,所以证明了：PrPc在阿霉素处理情况下的抗凋亡功能与p53通路无关。
Objective:To investigate the role of cellular prion protein (PrPc) in breast cancer cells apoptosis.
Methods:Using Western-bloting method for protein detection; immune fluorescence method for target protein localization and semi quantitative analysis; retroviral vector RNAi for establishing PrPc knockdown stable cell lines; MTT method for the determination of cell viability and normal cell growth curve; trypan blue staining method for determining live/dead cell ratio.
Results:The MDA-MB-435cell line is a estrogen receptor negative and PrPc high expression human breast cancer cell line. PrPc knockdown stable cell lines (abbreviated as MDA-MB-435-siPrP:siPrP) and control cell lines (abbreviated as MDA-MB-435-siLuc:siLuc) were successfully constructed using retroviral vectors expressing RNAi targeting PrP or luciferase.
Our results revealed that PrPc plays dramatically different roles in cell death caused by various factors.(1) In Doxorubicin treatment or glucose deprivation, siPrP cell line exhibited significantly more tolerance than siLuc cell lines, indicating a pro-apoptotic function of PrPc;(2) however, in rotenone-induced cell death, a higher cell death was observed in siPrP cell line compared to the control siLuc cells, suggesting an anti-apoptotic function of PrPc;(3) in hydrogen peroxide (H2O2), paclitaxel and staurosporine treatments, siPrP cells and siLuc cell lines did not show clear differences, suggesting that PrPc does not play a significant role in these cell death processes. Our results showed that, in the same cell line, PrPc may play different roles in cell deaths induced by various factors. In order to remove the additional effect caused by the stable cell line establishment process due to antibiotic screening of cell lines, we in transiently transfected siPrP and controlled siLuc plasmid to MDA-MB-435cell lines;48hours after transfection, repeat the doxorubicin experiment,results showed that PrPc downregulation of cell lines are still on adriamycin tolerance phenomenon; that of doxorubicin on siLuc and siPrP two cell lines of different effect was not due to stable cell lines construction process, but because of PrPc expression downregulated.
Moreover,research on the mechanism of siPrP cell tolerance by doxorubicin treatment, we found that siPrP cell line p-p53expression was higher in siLuc cell line after doxorubicin treatment,; due to MDA-MB-435cell line p53mutants, we transfect widetype p53in stable cell lines, the experimental results show that after up-regulation of p53,siPrP-p53were still more tolerance on doxorubicin treatment,we also showed that the pro-apoptotic function of PrPc in Doxorubicin-treated siPrP cells is p53pathway independent.
引文
[1]. Prusiner SB. Prions. Proc Natl Acad Sci U S A.1998 Nov 10;95(23):13363-83.
[2]. Meslin F, Conforti R, Mazouni C, Morel N, Tomasic G, Drusch F, Yacoub M, Sabourin JC, Grassi J, Delaloge S, Mathieu MC, Chouaib S, Andre F, Mehrpour M.Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. Ann Oncol.2007 Nov;18(11):1793-8.
[3]. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature.2001 May 24;411(6836):494-8.
[4]. Fire A.RNA-triggered gene silencing.Trends Genet.1999 Sep;15(9):358-63.
[5].利用RNAi逆转录病毒载体系统对人朊病毒蛋白表达的稳定抑制。徐文婧,王娣,王娟,杨怀义
[6]. "Doxorubicin (Systemic)." Mayo Clinic. Last updated on:June 15,1999. Retrieved on April 19,2007. Archived April 3,2007 at the Wayback Machine.
[7]. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA.Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.Mol Pharmacol. 1994 Apr;45(4):649-56.
[8]. Momparler RL, Karon M, Siegel SE, Avila F.Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.Cancer Res.1976 Aug;36(8):2891-5.
[9]. Ling YH, Priebe W, Perez-Soler R.Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.Cancer Res.1993 Apr 15;53(8):1845-52.
[10]. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E.Doxorubicin-induced DNA degradation in murine thymocytes.Mol Pharmacol.1994 Nov;46(5):901-8.
[11]. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R.Ceramide synthase mediates daunorubicin-induced apoptosis:an alternative mechanism for generating death signals.Cell.1995 Aug 11;82(3):405-14.
[12]. Jaffrezou J-P, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis:triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15:2417-2424,1996.
[13]. Meslin F, HamaV A, Gao P, Jalil A, Cahuzac N, Chouaib S, Mehrpour M.Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.Cancer Res.2007 Nov 15;67(22):10910-9.
[14]. International Programme on Chemical Safety (IPCS), Rotenone Health and Safety Guide, Number 73.
[15]. Summary of the article by Dr. Greenamyre on pesticides and Parkinson's Disease at ninds.nih.gov
[16]. McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE.Prion protein accumulation and neuroprotection in hypoxic brain damage.Am J Pathol.2004 Jul;165(1):227-35.
[17]. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y, Masuma R.A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization..J Antibiot (Tokyo).1977 Apr;30(4):275-82.
[18]. Ruegg UT, Burgess GM.Staurosporine, K-252 and UCN-01:potent but nonspecific inhibitors of protein kinases.Trends Pharmacol Sci.1989 Jun;10(6):218-20.
[19]. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.A quantitative analysis of kinase inhibitor selectivity.Nat Biotechnol. 2008 Jan;26(1):127-32.
[20]. Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR.Molecular mechanism of staurosporine-induced apoptosis in osteoblasts.Pharmacol Res.2000 Oct;42(4):373-81.
[21]. Bharadwaj R, Yu H.The spindle checkpoint, aneuploidy, and cancer.Oncogene. 2004 Mar 15;23(11):2016-27.
[22], Brito DA, Yang Z, Rieder CL.Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied.J Cell Biol.2008 Aug 25;182(4):623-9.
[23]. Sakudo A, Lee DC, Li S, Nakamura T, Matsumoto Y, Saeki K, Itohara S, Ikuta K, Onodera T.PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line.Biochem Biophys Res Commun.2005 Mar4;328(1):14-9.
[24]. Sakudo A, Lee DC, Nishimura T, Li S, Tsuji S, Nakamura T, Matsumoto Y, Saeki K, Itohara S, Ikuta K, Onodera T.Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase.Biochem Biophys Res Commun.2005 Jan 21;326(3):600-6.
[25]. Sakudo A, Lee DC, Saeki K, Nakamura Y, Inoue K, Matsumoto Y, Itohara S, Onodera T.Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line.Biochem Biophys Res Commun.2003 Aug 29;308(3):660-7.
[26]. Suhara T, Fukuo K, Sugimoto T, Morimoto S, Nakahashi T, Hata S, Shimizu M, Ogihara T.Hydrogen peroxide induces up-regulation of Fas in human endothelial cells.J Immunol.1998 Apr 15;160(8):4042-7.
[27]. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL, Kalyanaraman B.Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells:Role of ubiquitin-proteasome pathway.Proc Natl Acad Sci U S A.2003 Sep 16;100(19):10653-8.
[28]. Ballinger SW, Patterson C, Yan CN, Doan R, Burow DL, Young CG, Yakes FM, Van Houten B, Ballinger CA, Freeman BA, Runge MS.Hydrogen peroxide-and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells.Circ Res.2000 May 12;86(9):960-6.
[29]. Lin SJ, Shyue SK, Liu PL, Chen YH, Ku HH, Chen JW, Tarn KB, Chen YL.Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways.J Mol Cell Cardiol.2004Jan;36(1):129-39.
[30]. Wu Y, Wang D, Wang X, Wang Y, Ren F, Chang D, Chang Z, Jia B.Caspase 3 is activated through caspase 8 instead of caspase 9 during H2O2-induced apoptosis in HeLa cells.Cell Physiol Biochem.2011;27(5):539-46.
[31]. Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ, Tang F, Chen ZQ, Liu XP, Xu ZD.The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.Cell Mol Life Sci.2009 Feb;66(3):504-15.
[32]. Paitel E, Fahraeus R, Checler F.Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation.J Biol Chem.2003 Mar 21;278(12):10061-6.
[33]. Paitel E, Sunyach C, Alves da Costa C, Bourdon JC, Vincent B, Checler F.Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels.J Biol Chem.2004 Jan 2;279(1):612-8.
[34]. Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, Krasemann S, Deslys JP, Dormont D, Lasmezas C1, Weiss S.The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein.EMBO J.2001 Nov 1;20(21):5863-75.
[35]. Sunyach C, Checler F.Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis.J Neurochem.2005 Mar;92(6):1399-407.
[36]. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE.Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction.J Biol Chem.2002 Sep 20;277(38):35509-15.
[37]. Sunyach C, Cisse MA, da Costa CA, Vincent B, Checler F.The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation.J Biol Chem.2007 Jan 19;282(3):1956-63. Epub 2006 Nov 22.
[38]. Pharoah PD, Day NE, Caldas C.Somatic mutations in the p53 gene and prognosis in breast cancer:a meta-analysis.Br J Cancer.1999 Aug;80(12):1968-73.
[39]. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J.Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.Clin Cancer Res. 2000 Oct;6(10):3923-31.
[40]. Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, Bergh J.Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort.Cancer Res.2001 Nov 15;61(22):8317-21.
[41]. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J.The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.Cancer Res.2001 Mar 1;61(5):2256-60.
[42]. Aas T, B(?)rresen AL, Geisler S, Smith-S(?)rensen B, Johnsen H, Varhaug JE, Akslen LA, L(?)nning PE.Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.Nat Med.1996 Jul;2(7):811-4.
[43]. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R.Tp53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Re 6:50-56,2000.
[44]. M. Diarra-Mehrpour, S. Arrabal, A. Jalil, X. Pinson, C. Gaudin, G. Pietu, A. Pitaval, H. Ripoche, M. Eloit, D. Dormont, S. Chouaib, Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death, Cancer Res.200464:719-727.
[45]. J.G. Clohessy, J. Zhuang, J. de Boer, G. Gil-Gomez, H.J. Brady, Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis, J. Biol. Chem.2006281:5750-5759.
[46]. Lazarini F, Castelnau P, Chermann JF, Deslys JP, Dormont D.Modulation of prion protein gene expression by growth factors in cultured mouse astrocytes and PC-12 cells. Brain Res.199422:268-274,.
[47]. J. Collinge, M.A. Whittington, K.C. Sidle, C.J. Smith, M.S. Palmer, A.R. Clarke, J.G. efferys, Prion protein is necessary for normal synaptic function,Nature.1994370:295-297.
[48]. J.R. Criado, M. Sanchez-Alavez, B. Conti, J.L Giacchino, D.N. Wills, S.J. Henriksen, R. Race, J.C. Manson, B. Chesebro, M.B. Oldstone, Mice devoid of priori protein have cognitive deficits that are rescued by reconstitution of PrP in neurons, Neurobiol. Dis.2005.19:255-265.
[49]. B. Lobao-Soares, R. Walz, C.G. Carlotti Jr., A.C. Sakamoto, F. Calvo, A.L Terzian, J.A. da Silva, L. Wichert-Ana, N.C. Coimbra, M.M. Bianchin, Cellular prion protein regulates the motor behavior performance and anxiety-induced responses in genetically modified mice, Behav. Brain Res.2007183:87-94.
[50]. H. Khosravani, Y. Zhang, S. Tsutsui, S. Hameed, C. Altier, J. Hamid, L. Chen, M. Villemaire, Z. Ali, F.R. Jirik, G.W. Zamponi, Prion protein attenuates excitotoxicity by inhibiting NMDA receptors, J. Cell Biol.2008 181:551-565.
[51]. P.C. Pauly, D.A. Harris, Copper stimulates endocytosis of the prion protein, J. Biol. Chem.1998.273:33107-33110.
[52]. Mange, O. Milhavet, D. Umlauf, D. Harris, S. Lehmann, PrPdependent cell adhesion in N2a neuroblastoma cells, FEBS Lett.2002.514:159-162.
[53]. R. Linden, V.R. Martins, M.A. Prado, M. Cammarota, I. Izquierdo, R.R. Brentani, Physiology of the prion protein, Physiol. Rev.200888:673-728.
[54]. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA.2006 103: 3416-3421.
[55]. Williams RW, Herrup K. The control of neuron number. Annu Rev Neurosci.198811:423-53.
[56]. Mabbott NA, Brown KL, Manson J, Bruce ME. T-lymphocyte activation and the cellular form of the prion protein, lmmunology.1997 92:161-165.
[57]. Mazzoni IE, Ledebur HC Jr, Paramithiotis E, Cashman N. Lymphoid signal transduction mechanisms linked to cellular prion protein. Biochem Cell Biol.2005 83:644-653.
[58]. Dodelet VC, Cashman NR. Prion protein expression in human leukocyte differentiation. Blood.199891:1556-1561.
[591. Gougoumas DD, Vizirianakis IS, Tsiftsoglou AS. Transcriptional activation of prion protein gene in growth-arrested and differentiated mouse erythroleukemia and human neoplastic cells. Exp Cell Res.2001264:408-417.
[60]. Sales N, Hassig R, Rodolfo K, Di Giamberardino L, Traiffort E, Ruat M, Fretier P, Moya KL. Developmental expression of the cellular prion protein in elongating axcns. Eur J Neurosci 15:1163-1177,2002.
[61]. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA.2006 103: 3416-3421.
[62]. Galvan C, Camoletto PG, Dotti CG, Aguzzi A, Ledesma MD. Proper axonal distribution of PrP(C) depends on cholesterol-sphingomyelin-enriched membrane domains and is developmentally regulated in hippocampal neurons. Mol Cell Neurosci.200530:304-315.
[63]. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem.2001276:39145-39149.
[64]. Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem.2005 95: 1373-1386.
[65]. Roucou X, Guo Q, Zhang Y, Goodyer CG, LeBlanc AC. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J Biol Chem.2003278:40877-40881.
[66]. S. Mouillet-Richard, M. Pietri, B. Schneider, C. Vidal, V. Mutel, J.M. Launay, O. Kellermann, Modulation of serotonergic receptor signaling and cross-talk by prion protein, J. Biol. Chem.2005 280:4592-4601.
[67]. H. Sauer, K. Wefer, V. Vetrugno, M. Pocchiari, C. Gissel, A. Sachinidis, J. Hescheler, M. Wartenberg, Regulation of intrinsic prion protein by growth factors and TNF-alpha:the role of intracellular reactive oxygen species, Free Radic. Biol. Med.200335:586-594.
[68]. Li A, Harris DA. Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem.2005280:17430-17434.
[69]. Liang J, Pan YL, Ning XX, Sun U, Lan M, Hong L, Du JP, Liu N, Liu CJ, Qiao TD, Fan DM. Overexpression of PrPc and its antiapoptosis function in gastric cancer. Tumour Biol.2006 27:84-91.
[70]. Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, Pitaval A, Ripoche H, Eloit M, Dormont D, Chouaib S. Priori protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res.200464:719-727.
[71]. Kim BH, Lee HG, Choi JK, Kim Jl, Choi EK, Carp R1, Kim YS. The cellular prion protein (PrPc) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation. Brain Res.2004124:40-50.
[72]. Gains MJ, Roth KA, LeBlanc AC. Prion protein protects against ethanol-induced Bax-mediated cell death in vivo. Neuroreport.2006 17: 903-906.
[73]. Coulpier M, Messiaen S, Boucreaux D, Eloit M. Axotomyinduced motoneuron death is delayed in mice overexpressing PrPc. Neuroscience.2006 141:1827-1834.
[74]. Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang SL, Torchia M, Carlson GA, Prusiner SB. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell.1994 76:117-129.
[75]. Paitel E, Alves da Costa C, Vilette D, Grassi J, Checler F. Overexpression of PrPc triggers caspase 3 activation:potentiation by proteasome inhibitors and blockade by anti-PrP antibodies. J Neurochem.200283:1208-1214.
[76]. Paitel E, Fahraeus R, Checler F. Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation. J Biol Chem.2003278:10061-10066.
[77]. Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ.200512: 783-795.
[78]. Chen S, Mange A, Dong L, Lehmann S, Schachner M. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol Cell Neurosci.2003 22:227-233.
[79]. G. Wu, K. Nakajima, N. Takeyama, M. Yukawa, Y. Taniuchi, A. Sakudo, T. Onodera, Species-specific anti-apoptotic activity of cellular prion protein in a mouse PrP-deficient neuronal cell line transfected with mouse, hamster, and bovine Prnp, Neurosci. Lett.2008446:11-15.
[80]. Rocha M, Martins RA, Linden R. Activation of NMDA receptors protects against glutamate neurotoxicity in the retina:evidence for the involvement of neurotrophins. Brain Res.1999827:79-92.
[81].Nykjaer A, Willnow TE, Petersen CM. p75NTR:live or let die. Curr Opin Neurobiol.200515:49-57.
[2]. Meslin F, Conforti R, Mazouni C, Morel N, Tomasic G, Drusch F, Yacoub M, Sabourin JC, Grassi J, Delaloge S, Mathieu MC, Chouaib S, Andre F, Mehrpour M.Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. Ann Oncol.2007 Nov;18(11):1793-8.
[3]. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature.2001 May 24;411(6836):494-8.
[4]. Fire A.RNA-triggered gene silencing.Trends Genet.1999 Sep;15(9):358-63.
[5].利用RNAi逆转录病毒载体系统对人朊病毒蛋白表达的稳定抑制。徐文婧,王娣,王娟,杨怀义
[6]. "Doxorubicin (Systemic)." Mayo Clinic. Last updated on:June 15,1999. Retrieved on April 19,2007. Archived April 3,2007 at the Wayback Machine.
[7]. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA.Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.Mol Pharmacol. 1994 Apr;45(4):649-56.
[8]. Momparler RL, Karon M, Siegel SE, Avila F.Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.Cancer Res.1976 Aug;36(8):2891-5.
[9]. Ling YH, Priebe W, Perez-Soler R.Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.Cancer Res.1993 Apr 15;53(8):1845-52.
[10]. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E.Doxorubicin-induced DNA degradation in murine thymocytes.Mol Pharmacol.1994 Nov;46(5):901-8.
[11]. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R.Ceramide synthase mediates daunorubicin-induced apoptosis:an alternative mechanism for generating death signals.Cell.1995 Aug 11;82(3):405-14.
[12]. Jaffrezou J-P, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis:triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15:2417-2424,1996.
[13]. Meslin F, HamaV A, Gao P, Jalil A, Cahuzac N, Chouaib S, Mehrpour M.Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.Cancer Res.2007 Nov 15;67(22):10910-9.
[14]. International Programme on Chemical Safety (IPCS), Rotenone Health and Safety Guide, Number 73.
[15]. Summary of the article by Dr. Greenamyre on pesticides and Parkinson's Disease at ninds.nih.gov
[16]. McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE.Prion protein accumulation and neuroprotection in hypoxic brain damage.Am J Pathol.2004 Jul;165(1):227-35.
[17]. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y, Masuma R.A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization..J Antibiot (Tokyo).1977 Apr;30(4):275-82.
[18]. Ruegg UT, Burgess GM.Staurosporine, K-252 and UCN-01:potent but nonspecific inhibitors of protein kinases.Trends Pharmacol Sci.1989 Jun;10(6):218-20.
[19]. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.A quantitative analysis of kinase inhibitor selectivity.Nat Biotechnol. 2008 Jan;26(1):127-32.
[20]. Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR.Molecular mechanism of staurosporine-induced apoptosis in osteoblasts.Pharmacol Res.2000 Oct;42(4):373-81.
[21]. Bharadwaj R, Yu H.The spindle checkpoint, aneuploidy, and cancer.Oncogene. 2004 Mar 15;23(11):2016-27.
[22], Brito DA, Yang Z, Rieder CL.Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied.J Cell Biol.2008 Aug 25;182(4):623-9.
[23]. Sakudo A, Lee DC, Li S, Nakamura T, Matsumoto Y, Saeki K, Itohara S, Ikuta K, Onodera T.PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line.Biochem Biophys Res Commun.2005 Mar4;328(1):14-9.
[24]. Sakudo A, Lee DC, Nishimura T, Li S, Tsuji S, Nakamura T, Matsumoto Y, Saeki K, Itohara S, Ikuta K, Onodera T.Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase.Biochem Biophys Res Commun.2005 Jan 21;326(3):600-6.
[25]. Sakudo A, Lee DC, Saeki K, Nakamura Y, Inoue K, Matsumoto Y, Itohara S, Onodera T.Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line.Biochem Biophys Res Commun.2003 Aug 29;308(3):660-7.
[26]. Suhara T, Fukuo K, Sugimoto T, Morimoto S, Nakahashi T, Hata S, Shimizu M, Ogihara T.Hydrogen peroxide induces up-regulation of Fas in human endothelial cells.J Immunol.1998 Apr 15;160(8):4042-7.
[27]. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL, Kalyanaraman B.Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells:Role of ubiquitin-proteasome pathway.Proc Natl Acad Sci U S A.2003 Sep 16;100(19):10653-8.
[28]. Ballinger SW, Patterson C, Yan CN, Doan R, Burow DL, Young CG, Yakes FM, Van Houten B, Ballinger CA, Freeman BA, Runge MS.Hydrogen peroxide-and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells.Circ Res.2000 May 12;86(9):960-6.
[29]. Lin SJ, Shyue SK, Liu PL, Chen YH, Ku HH, Chen JW, Tarn KB, Chen YL.Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways.J Mol Cell Cardiol.2004Jan;36(1):129-39.
[30]. Wu Y, Wang D, Wang X, Wang Y, Ren F, Chang D, Chang Z, Jia B.Caspase 3 is activated through caspase 8 instead of caspase 9 during H2O2-induced apoptosis in HeLa cells.Cell Physiol Biochem.2011;27(5):539-46.
[31]. Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ, Tang F, Chen ZQ, Liu XP, Xu ZD.The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.Cell Mol Life Sci.2009 Feb;66(3):504-15.
[32]. Paitel E, Fahraeus R, Checler F.Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation.J Biol Chem.2003 Mar 21;278(12):10061-6.
[33]. Paitel E, Sunyach C, Alves da Costa C, Bourdon JC, Vincent B, Checler F.Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels.J Biol Chem.2004 Jan 2;279(1):612-8.
[34]. Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, Krasemann S, Deslys JP, Dormont D, Lasmezas C1, Weiss S.The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein.EMBO J.2001 Nov 1;20(21):5863-75.
[35]. Sunyach C, Checler F.Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis.J Neurochem.2005 Mar;92(6):1399-407.
[36]. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE.Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction.J Biol Chem.2002 Sep 20;277(38):35509-15.
[37]. Sunyach C, Cisse MA, da Costa CA, Vincent B, Checler F.The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation.J Biol Chem.2007 Jan 19;282(3):1956-63. Epub 2006 Nov 22.
[38]. Pharoah PD, Day NE, Caldas C.Somatic mutations in the p53 gene and prognosis in breast cancer:a meta-analysis.Br J Cancer.1999 Aug;80(12):1968-73.
[39]. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J.Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.Clin Cancer Res. 2000 Oct;6(10):3923-31.
[40]. Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, Bergh J.Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort.Cancer Res.2001 Nov 15;61(22):8317-21.
[41]. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J.The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.Cancer Res.2001 Mar 1;61(5):2256-60.
[42]. Aas T, B(?)rresen AL, Geisler S, Smith-S(?)rensen B, Johnsen H, Varhaug JE, Akslen LA, L(?)nning PE.Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.Nat Med.1996 Jul;2(7):811-4.
[43]. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R.Tp53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Re 6:50-56,2000.
[44]. M. Diarra-Mehrpour, S. Arrabal, A. Jalil, X. Pinson, C. Gaudin, G. Pietu, A. Pitaval, H. Ripoche, M. Eloit, D. Dormont, S. Chouaib, Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death, Cancer Res.200464:719-727.
[45]. J.G. Clohessy, J. Zhuang, J. de Boer, G. Gil-Gomez, H.J. Brady, Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis, J. Biol. Chem.2006281:5750-5759.
[46]. Lazarini F, Castelnau P, Chermann JF, Deslys JP, Dormont D.Modulation of prion protein gene expression by growth factors in cultured mouse astrocytes and PC-12 cells. Brain Res.199422:268-274,.
[47]. J. Collinge, M.A. Whittington, K.C. Sidle, C.J. Smith, M.S. Palmer, A.R. Clarke, J.G. efferys, Prion protein is necessary for normal synaptic function,Nature.1994370:295-297.
[48]. J.R. Criado, M. Sanchez-Alavez, B. Conti, J.L Giacchino, D.N. Wills, S.J. Henriksen, R. Race, J.C. Manson, B. Chesebro, M.B. Oldstone, Mice devoid of priori protein have cognitive deficits that are rescued by reconstitution of PrP in neurons, Neurobiol. Dis.2005.19:255-265.
[49]. B. Lobao-Soares, R. Walz, C.G. Carlotti Jr., A.C. Sakamoto, F. Calvo, A.L Terzian, J.A. da Silva, L. Wichert-Ana, N.C. Coimbra, M.M. Bianchin, Cellular prion protein regulates the motor behavior performance and anxiety-induced responses in genetically modified mice, Behav. Brain Res.2007183:87-94.
[50]. H. Khosravani, Y. Zhang, S. Tsutsui, S. Hameed, C. Altier, J. Hamid, L. Chen, M. Villemaire, Z. Ali, F.R. Jirik, G.W. Zamponi, Prion protein attenuates excitotoxicity by inhibiting NMDA receptors, J. Cell Biol.2008 181:551-565.
[51]. P.C. Pauly, D.A. Harris, Copper stimulates endocytosis of the prion protein, J. Biol. Chem.1998.273:33107-33110.
[52]. Mange, O. Milhavet, D. Umlauf, D. Harris, S. Lehmann, PrPdependent cell adhesion in N2a neuroblastoma cells, FEBS Lett.2002.514:159-162.
[53]. R. Linden, V.R. Martins, M.A. Prado, M. Cammarota, I. Izquierdo, R.R. Brentani, Physiology of the prion protein, Physiol. Rev.200888:673-728.
[54]. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA.2006 103: 3416-3421.
[55]. Williams RW, Herrup K. The control of neuron number. Annu Rev Neurosci.198811:423-53.
[56]. Mabbott NA, Brown KL, Manson J, Bruce ME. T-lymphocyte activation and the cellular form of the prion protein, lmmunology.1997 92:161-165.
[57]. Mazzoni IE, Ledebur HC Jr, Paramithiotis E, Cashman N. Lymphoid signal transduction mechanisms linked to cellular prion protein. Biochem Cell Biol.2005 83:644-653.
[58]. Dodelet VC, Cashman NR. Prion protein expression in human leukocyte differentiation. Blood.199891:1556-1561.
[591. Gougoumas DD, Vizirianakis IS, Tsiftsoglou AS. Transcriptional activation of prion protein gene in growth-arrested and differentiated mouse erythroleukemia and human neoplastic cells. Exp Cell Res.2001264:408-417.
[60]. Sales N, Hassig R, Rodolfo K, Di Giamberardino L, Traiffort E, Ruat M, Fretier P, Moya KL. Developmental expression of the cellular prion protein in elongating axcns. Eur J Neurosci 15:1163-1177,2002.
[61]. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA.2006 103: 3416-3421.
[62]. Galvan C, Camoletto PG, Dotti CG, Aguzzi A, Ledesma MD. Proper axonal distribution of PrP(C) depends on cholesterol-sphingomyelin-enriched membrane domains and is developmentally regulated in hippocampal neurons. Mol Cell Neurosci.200530:304-315.
[63]. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem.2001276:39145-39149.
[64]. Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem.2005 95: 1373-1386.
[65]. Roucou X, Guo Q, Zhang Y, Goodyer CG, LeBlanc AC. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J Biol Chem.2003278:40877-40881.
[66]. S. Mouillet-Richard, M. Pietri, B. Schneider, C. Vidal, V. Mutel, J.M. Launay, O. Kellermann, Modulation of serotonergic receptor signaling and cross-talk by prion protein, J. Biol. Chem.2005 280:4592-4601.
[67]. H. Sauer, K. Wefer, V. Vetrugno, M. Pocchiari, C. Gissel, A. Sachinidis, J. Hescheler, M. Wartenberg, Regulation of intrinsic prion protein by growth factors and TNF-alpha:the role of intracellular reactive oxygen species, Free Radic. Biol. Med.200335:586-594.
[68]. Li A, Harris DA. Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem.2005280:17430-17434.
[69]. Liang J, Pan YL, Ning XX, Sun U, Lan M, Hong L, Du JP, Liu N, Liu CJ, Qiao TD, Fan DM. Overexpression of PrPc and its antiapoptosis function in gastric cancer. Tumour Biol.2006 27:84-91.
[70]. Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, Pitaval A, Ripoche H, Eloit M, Dormont D, Chouaib S. Priori protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res.200464:719-727.
[71]. Kim BH, Lee HG, Choi JK, Kim Jl, Choi EK, Carp R1, Kim YS. The cellular prion protein (PrPc) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation. Brain Res.2004124:40-50.
[72]. Gains MJ, Roth KA, LeBlanc AC. Prion protein protects against ethanol-induced Bax-mediated cell death in vivo. Neuroreport.2006 17: 903-906.
[73]. Coulpier M, Messiaen S, Boucreaux D, Eloit M. Axotomyinduced motoneuron death is delayed in mice overexpressing PrPc. Neuroscience.2006 141:1827-1834.
[74]. Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang SL, Torchia M, Carlson GA, Prusiner SB. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell.1994 76:117-129.
[75]. Paitel E, Alves da Costa C, Vilette D, Grassi J, Checler F. Overexpression of PrPc triggers caspase 3 activation:potentiation by proteasome inhibitors and blockade by anti-PrP antibodies. J Neurochem.200283:1208-1214.
[76]. Paitel E, Fahraeus R, Checler F. Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation. J Biol Chem.2003278:10061-10066.
[77]. Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ.200512: 783-795.
[78]. Chen S, Mange A, Dong L, Lehmann S, Schachner M. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol Cell Neurosci.2003 22:227-233.
[79]. G. Wu, K. Nakajima, N. Takeyama, M. Yukawa, Y. Taniuchi, A. Sakudo, T. Onodera, Species-specific anti-apoptotic activity of cellular prion protein in a mouse PrP-deficient neuronal cell line transfected with mouse, hamster, and bovine Prnp, Neurosci. Lett.2008446:11-15.
[80]. Rocha M, Martins RA, Linden R. Activation of NMDA receptors protects against glutamate neurotoxicity in the retina:evidence for the involvement of neurotrophins. Brain Res.1999827:79-92.
[81].Nykjaer A, Willnow TE, Petersen CM. p75NTR:live or let die. Curr Opin Neurobiol.200515:49-57.